Explore tirzepatide’s unique dual GIP and GLP-1 receptor agonism, the SURMOUNT-1 trial’s 22.5% weight loss results, dosing schedule, and differences between Mounjaro and Zepbound.
Explore tirzepatide’s unique dual GIP and GLP-1 receptor agonism, the SURMOUNT-1 trial’s 22.5% weight loss results, dosing schedule, and differences between Mounjaro and Zepbound.